Working… Menu
Trial record 7 of 108 for:    "Vascular Hemostatic Disease" | "Doxorubicin"

Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00837200
Recruitment Status : Terminated (PI said to close accrual do to funding)
First Posted : February 5, 2009
Results First Posted : August 20, 2014
Last Update Posted : July 24, 2017
Information provided by (Responsible Party):
Joseph Drabick, Milton S. Hershey Medical Center

Brief Summary:
This is an exploratory study to study the efficacy of combination regimen of Oncaspar/Doxil/Decadron (ODD) in patients with refractory lymphoid malignancies. Patients with any form of lymphoid malignancy will be eligible: acute lymphoblastic leukemia, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma and plasma cell leukemia. Patients must have failed standard regimens for their cancers and could have had unlimited number of prior regimens. Patients will be staged appropriately for their disease with clinical examination, laboratory tests, and imaging studies. Both Oncaspar and Doxil will be given on day 1 and 15. Patients will be clinically evaluated prior to each cycle and will have disease assessments every 2 cycles. Responding patients will continue therapy until disease progression or excessive toxicity. Responders who are candidates for allogenic stem cell transplantation could go to conditioning chemotherapy and stem cell transplant after 4 cycles of ODD.

Condition or disease Intervention/treatment Phase
Non-hodgkins Lymphoma Hodgkins Lymphoma Multiple Myeloma Drug: Oncaspar, Doxil, Decadron Phase 2

Detailed Description:
This phase II trial will study the effectiveness of a combination regimen which includes Oncaspar (PEG-asparaginase), Doxil (PEG-liposomal doxorubicin), and Decadron (ODD) in terms of disease response against refractory lymphoid malignancies. Asparaginase is an enzyme that depletes asparagines, a key amino acid for survival and growth of malignant lymphocytes. Its depletion results in death of the neoplastic cell. Asparagine depletion has induced a significant improvement of clinical outcomes in acute lymphoblastic leukemia (ALL) and L-asparaginase has been a mainstay for more than 30 years in the treatment of ALL. Although this drug has been used primarily in ALL, promising results have been reported even in other non-ALL lymphoid malignancies, such as chronic lymphocytic leukemia (CLL), prolymphocytic leukemia, refractory non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). One of the main goals of this trial is to measure the asparaginase level as a surrogate marker of asparagine depletion with Oncaspar, a PEG-enhanced version of E. coli L-asparaginase. The therapeutic value of the simple, non-pegylated form of L-asparaginase is limited by its short half-life and propensity to cause allergic reactions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Pilot Efficacy Trial of the Combination Regimen Oncaspar/Doxil/Decadron (ODD) in Patients With Refractory Lymphoid Malignancies
Study Start Date : March 2009
Actual Primary Completion Date : January 2011
Actual Study Completion Date : October 2013

Arm Intervention/treatment
Experimental: Oncaspar, Doxil, Decadron Regimen
Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.
Drug: Oncaspar, Doxil, Decadron
Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.
Other Names:
  • PEG-asparaginase
  • PEG-liposomal doxorubicin

Primary Outcome Measures :
  1. Tumor Response [ Time Frame: 16 weeks ]
    • Leukemias mainly w/peripheral blood counts/diff every 2 wks/CLL, CT scan before initiation of study, 2nd CT after EOT, no CT at FU
    • Lymphomas restaged w/CT scans of chest/abdomen/pelvis or PET/CT scans after 2 cycles
    • MM monitored w/tumor markers monthly Quantitative immunoglobulins/SPEP w/quantitative M component in MM pts producing full antibody, UPEP w/ quantitative Bence-Jones in MM pts producing only light chains/Serum free light chains obtained all pts/Skeletal surveys at baseline Tumor responses:CR complete resolution of all detectable clinical/radiographic evidence of disease, disappearance of all disease related symptoms, and normalization of biochemical abnormalities for at least 6 wks following treatment and no BM infiltration;PR reduction of all measurable lesions by 50% or more/no new lesions;SD not fulfilling PR criteria/no evidence disease progression;PD increase original tumor mass by more than 25% lesion/new lesion
    • Stable disease > 2mo was a response

  2. Study Specific Measure (Response) [ Time Frame: 16 Weeks ]
  3. Study Specific Measure (Number of Participants Taken Off Study) [ Time Frame: 16 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically documented lymphoid malignancies, regardless of their origin (B,T or NK). These include ALL, CLL, HL, NHL, MM and PCL.
  • Patients must have failed at least one standard regimen of chemotherapy for their illness. They may have had unlimited prior regimens.
  • Performance status of ≤ 2 as per ECOG scale.
  • ALT < 2.5 times the upper limit of normal
  • Anticipated life expectancy of at least 12 weeks
  • Patients will be allowed to have baseline cytopenias, but ANC should be >200/μl and a platelet count > 25,000/ μl (within 2 weeks of starting therapy).
  • Patients must have a serum creatinine level ≤ 2 mg/dL (within 2 weeks of starting therapy).
  • Male or female adults of at least 18 years of age.
  • Signed written informed consent and willingness to meet follow-up schedule and study procedure obligations
  • Left Ventricular Ejection Fraction (LVEF) > 40% by echocardiogram or MUGA scan performed within 60 days prior to registration
  • Women and men of childbearing potential must agree to employ adequate contraception to prevent pregnancy while on therapy.

Exclusion Criteria:

  • Chemotherapy or radiotherapy received within the previous 2 weeks.
  • Uncontrolled, active infection requiring IV antibiotics.
  • Psychiatric illness that could potentially interfere with the completion of treatment according to this protocol.
  • Pregnant or potential for pregnancy.
  • Breast-feeding.
  • Prior asparaginase therapy complicated by pancreatitis, allergic reaction, hemorrhagic event, or thrombosis
  • Previous treatment with pegylated asparaginase
  • Prior doxorubicin exposure, more than 400 mg/m2
  • Clinically significant CHF
  • No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease free for at least three years. Prior malignancy is acceptable provided there has been no evidence of disease within the three year interval.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00837200

Layout table for location information
United States, Pennsylvania
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States, 17070
Sponsors and Collaborators
Milton S. Hershey Medical Center
Layout table for investigator information
Principal Investigator: Joseph J. Drabick, MD Penn State University

Layout table for additonal information
Responsible Party: Joseph Drabick, Professor of Medicine, Milton S. Hershey Medical Center Identifier: NCT00837200     History of Changes
Other Study ID Numbers: 08-007
First Posted: February 5, 2009    Key Record Dates
Results First Posted: August 20, 2014
Last Update Posted: July 24, 2017
Last Verified: June 2017
Keywords provided by Joseph Drabick, Milton S. Hershey Medical Center:
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemostatic Disorders
Liposomal doxorubicin
Multiple Myeloma
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplasms, Plasma Cell
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Dexamethasone acetate
BB 1101
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents